Accretion Pharmaceuticals LtdQ3 FY25Pharmaceuticals & Biotechnology

Accretion Pharmaceuticals Ltd

Q3 FY25 Earnings Call Analysis

Management growth scorecard

Revenue

Category 1

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Revenue guidance

Category 1

→The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue.
→Management indicated optimism for continued rapid sales growth in upcoming years, supported by a healthy order book and expanding export markets.
→They anticipate leveraging newly added production capacity (with around a 40% capacity increase post-IPO), along with improved utilization and product mix, to drive volume growth.
→FY '26 revenue is expected to surpass last year's INR57 crores significantly, aiming around INR120-130 crores based on current momentum.
→The company plans to expand product registrations in new geographies (e.g., Rwanda, Nigeria, Cambodia) to bolster sales channels.
→Growth is supported by strategic bulk sourcing, supply diversification, efficiency gains, and tighter working capital management.
→While exact figures are not confirmed, management is confident in sustaining or improving existing growth rates going forward.

Category 2

→Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.
→The company anticipates EBITDA margins to improve from the current ~17% toward a steady-state of 20%-22%, as registration and scaling expenses normalize.
→Profit after tax (PAT) is projected to grow significantly; with confidence expressed in maintaining or exceeding current profit levels (e.g., PAT closer to INR 10 crores anticipated).
→Improved capacity utilization and expanded product registrations in multiple countries (e.g., Rwanda, Nigeria, Cambodia) will drive revenue and margin expansion.
→Operational efficiencies, bulk sourcing, supply diversification, and tighter working capital management are expected to enhance profitability.
→Long-term focus is on sustainable, profitable growth, value creation, and increasing return ratios supported by a healthy order book and strengthened balance sheet.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Accretion Pharmaceuticals Ltd and 1,400+ other companies.

→The company has recently completed a successful IPO in May 2025, raising INR29.75 crores.
→Proceeds from the IPO have been strategically utilized for manufacturing facility upgrades, debt repayment, and working capital augmentation.
→Short-term and long-term borrowings have drastically reduced due to loan repayments post-IPO.
→There is no mention of any immediate or planned new fundraising through debt or equity in the call.
→The company emphasizes maintaining a healthy capital structure with low debt-to-equity ratio and adequate liquidity for future expansion.
→Focus remains on profitable growth, working capital efficiency, and prudent capital management without indicating any additional fundraising efforts currently.

Yes

→The company currently has a good order book, which supports their confidence in maintaining momentum in upcoming quarters.
→They expect to sustain the growth rate seen in the first half of the year through efficient utilization of working capital and enhanced capacity.
→New product launches and expansion into new countries also contribute to anticipated revenue growth from the order book.
→The management confirms clarity on the existing order book and expects to deliver on these orders, contributing to PAT projections close to INR 10 crores for the year.
→Although specific numbers are not disclosed, the company expresses confidence based on established products and customer relationships.

Yes

→The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO.
→The capex includes upgrading manufacturing facilities with new equipment to enhance capacity and compliance.
→Future capex plans involve continued expansion and equipment upgradation to strengthen CDMO capabilities.
→Focus on expanding product registrations and regulatory approvals in markets like Rwanda, Nigeria, Cambodia, and others to support growth.
→Working capital has been augmented to support growing orders and ensure operational agility.
→The company aims to sustain double-digit growth with a balanced mix of domestic and export revenues backed by these investments.
→Loan repayments have reduced debt, maintaining a healthy capital structure with adequate liquidity for future expansions.

How does Accretion Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Accretion Pharmaceuticals Ltd

Rev 1Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Accretion Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.